Clinical Trial Detail

NCT ID NCT03004105
Title MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Selumetinib

Age Groups: adult senior

No variant requirements are available.